Home

About Us

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.

Learn More

Innovation

Cingulate is developing ADHD medications capable of achieving precise once-daily dosing using a novel erosion based controlled release technology that provides unrivaled control of drug release.

Learn More

Pipeline

Cingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. anxiety market.

Learn More

/ 3 / 3

COMPANY

Cingulate^® (CTx^®) is a biopharmaceutical company focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders.

PIPELINE

Cingulate^® currently has two product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

ADHD

Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood.

The Precision Timed Release™ Platform

The Precision Timed Release™ Platform is a triad of proprietary, sophisticated elements

Proprietary Erosion Barrier Layer (EBL)
Specialized compression technology
Semi-continuous manufacturing & real-time release

Explore

_{Computed Tomography Scan (CT scan) of CTx-1301 tablet}

About Us

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.

Innovation

Cingulate is developing ADHD medications capable of achieving precise once-daily dosing using a novel erosion based controlled release technology that provides unrivaled control of drug release.

Pipeline

Cingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. anxiety market.

Home

COMPANY

PIPELINE

ADHD

The Precision Timed Release™ Platform

Contact us